Literature DB >> 29226552

Spontaneously regressing brain lesions in Smith-Lemli-Opitz syndrome.

An N Dang Do1, Eva H Baker2, Katherine E Warren3, Simona E Bianconi1, Forbes D Porter1.   

Abstract

Smith-Lemli-Opitz syndrome (SLOS) is a metabolic disorder caused by an inborn error of cholesterol synthesis that affects the development of many organ systems. Malformations in the central nervous system typically involve midline structures and reflect abnormal growth and differentiation of neurons and supporting cells. Despite these defects in central nervous system development, brain tumor formation has only rarely been reported in association with SLOS. We present three individuals with SLOS and lesions in the basal ganglia or brainstem detected by MRI that were concerning for tumor formation. However, the individuals' clinical and neurological course remained stable, and the lesions regressed after several years. These lesions have similarities to spongiotic changes observed in individuals with neurofibromatosis type 1 (NF1). Notably, impaired activity of small GTPases is present in both SLOS and NF1, perhaps giving mechanistic insight into the formation of these lesions.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  GTPases; Smith-Lemli-Opitz syndrome; neurofibromatosis type 1; regressing brain lesions; spongiotic changes

Mesh:

Substances:

Year:  2017        PMID: 29226552      PMCID: PMC6309987          DOI: 10.1002/ajmg.a.38563

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  25 in total

Review 1.  Sonic hedgehog in Smith-Lemli-Opitz syndrome and tumor development.

Authors:  Marina Guizzetti; Lucio G Costa
Journal:  J Pediatr Hematol Oncol       Date:  2008-09       Impact factor: 1.289

2.  Age-related findings on MRI in neurofibromatosis type 1.

Authors:  Deepak S Gill; Shelley L Hyman; Adam Steinberg; Kathryn N North
Journal:  Pediatr Radiol       Date:  2006-08-16

Review 3.  The Smith-Lemli-Opitz syndrome.

Authors:  R I Kelley; R C Hennekam
Journal:  J Med Genet       Date:  2000-05       Impact factor: 6.318

4.  Sonic Hedgehog signaling in the mammalian brain.

Authors:  Elisabeth Traiffort; Elodie Angot; Martial Ruat
Journal:  J Neurochem       Date:  2010-03-10       Impact factor: 5.372

5.  Incidental findings on brain magnetic resonance imaging from 1000 asymptomatic volunteers.

Authors:  G L Katzman; A P Dagher; N J Patronas
Journal:  JAMA       Date:  1999-07-07       Impact factor: 56.272

Review 6.  Ras/Raf/ERK signalling and NF1.

Authors:  Marie C Harrisingh; Alison C Lloyd
Journal:  Cell Cycle       Date:  2004-10-17       Impact factor: 4.534

7.  Activation of Rho GTPases in Smith-Lemli-Opitz syndrome: pathophysiological and clinical implications.

Authors:  Xiao-Sheng Jiang; Christopher A Wassif; Peter S Backlund; Li Song; Lynne A Holtzclaw; Zheng Li; Alfred L Yergey; Forbes D Porter
Journal:  Hum Mol Genet       Date:  2010-01-12       Impact factor: 6.150

8.  Malignant intracranial germinoma in Smith-Lemli-Opitz syndrome: cholesterol homeostasis possibly connecting morphogenesis and cancer development.

Authors:  Hana Oslejskova; Vera Horinova; Jaroslav Sterba; Zdenek Pavelka; Dusica Babovic-Vuksanovic; Lenka Dubska; Dalibor Valik
Journal:  J Pediatr Hematol Oncol       Date:  2008-09       Impact factor: 1.289

Review 9.  Recent advances in neurofibromatosis type 1.

Authors:  Deepa Arun; David H Gutmann
Journal:  Curr Opin Neurol       Date:  2004-04       Impact factor: 5.710

10.  A defective response to Hedgehog signaling in disorders of cholesterol biosynthesis.

Authors:  Michael K Cooper; Christopher A Wassif; Patrycja A Krakowiak; Jussi Taipale; Ruoyu Gong; Richard I Kelley; Forbes D Porter; Philip A Beachy
Journal:  Nat Genet       Date:  2003-03-24       Impact factor: 38.330

View more
  1 in total

1.  Temporal changes in the brain lipidome during neurodevelopment of Smith-Lemli-Opitz syndrome mice.

Authors:  Amy Li; Kelly M Hines; Dylan H Ross; James W MacDonald; Libin Xu
Journal:  Analyst       Date:  2022-04-11       Impact factor: 5.227

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.